These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24992906)

  • 1. GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth.
    Luo C; Shibata K; Suzuki S; Kajiyama H; Senga T; Koya Y; Daimon M; Yamashita M; Kikkawa F
    Oncol Rep; 2014 Sep; 32(3):913-21. PubMed ID: 24992906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
    Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G
    Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
    Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
    Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
    Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
    Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
    Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy.
    Wiedemeyer K; Köbel M; Koelkebeck H; Xiao Z; Vashisht K
    Hum Pathol; 2020 Apr; 98():56-63. PubMed ID: 32017945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
    Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
    Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cancer peptide vaccine targeted glypican-3 antigen].
    Nakatsura T
    Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector.
    Liu Q; Yang Y; Tan X; Tao Z; Adah D; Yu S; Lu J; Zhao S; Qin L; Qin L; Chen X
    Oncotarget; 2017 Apr; 8(15):24785-24796. PubMed ID: 28445973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
    Suzuki S; Shibata K; Kikkawa F; Nakatsura T
    Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
    Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
    Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma.
    Takai H; Kato A; Kato C; Watanabe T; Matsubara K; Suzuki M; Kataoka H
    Liver Int; 2009 Aug; 29(7):1056-64. PubMed ID: 19141032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo.
    Umezu T; Shibata K; Shimaoka M; Kajiyama H; Yamamoto E; Ino K; Nawa A; Senga T; Kikkawa F
    Cancer Sci; 2010 Jan; 101(1):143-8. PubMed ID: 19860840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
    Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
    Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
    Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
    Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
    Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
    J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
    Sawada Y; Nakatsura T
    Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.